Aurobindo Pharma Limited (NSE:AUROPHARMA)
India
· Delayed Price · Currency is INR 1,143.80
-47.40 (-3.98%)
May 28, 2025, 3:30 PM IST
Aurobindo Pharma Employees
Aurobindo Pharma had 26,015 employees as of March 31, 2024. The number of employees increased by 2,564 or 10.93% compared to the previous year.
Employees
26,015
Change (1Y)
2,564
Growth (1Y)
10.93%
Revenue / Employee
12.19M INR
Profits / Employee
1.34M INR
Market Cap
666.64B
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| Sun Pharmaceutical Industries | 43,000 |
| Divi's Laboratories | 9,741 |
| Cipla | 27,764 |
| Apollo Hospitals Enterprise | 83,147 |
| Mankind Pharma | 19,540 |
| Zydus Lifesciences | 26,921 |
| Alkem Laboratories | 17,432 |
| Fortis Healthcare | 12,088 |
Aurobindo Pharma News
- 17 hours ago - Aurobindo Pharma shares fall over 2% after Citi maintains ‘Sell’ rating, cuts target price to Rs 1,100 - Business Upturn
- 19 hours ago - Motilal Oswal retains ‘Buy’ on Aurobindo Pharma, sets target at Rs 1,370 on strong EU presence, growth visibility - Business Upturn
- 19 hours ago - Nuvama cuts Aurobindo Pharma target to Rs 1,485 but retains ‘Buy’ on healthy EBITDA margin - Business Upturn
- 19 hours ago - Stocks to watch today on May 28: LIC, Aurobindo Pharma, Info Edge among top brokerage picks - Business Upturn
- 20 hours ago - CLSA trims FY26-27 estimates for Aurobindo Pharma after Pen-G plant disruption - Business Upturn
- 20 hours ago - HSBC advises to Buy Aurobindo Pharma, says long-term outlook intact despite EBITDA miss - Business Upturn
- 20 hours ago - Goldman Sachs retains ‘Buy’ on Aurobindo Pharma, sees value in stock despite gRevlimid headwinds - Business Upturn
- 20 hours ago - Citi maintains ‘Sell’ on Aurobindo Pharma after Q4 results, trims earnings estimates on margin risks post gRevlimid - Business Upturn